---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000095"
form_type: "8-K"
ticker: "OSUR"
cik: "0001116463"
company_name: "ORASURE TECHNOLOGIES INC"
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:05:56.270707+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OraSure CEO Stephen S. Tang to depart March 31, 2022; gets severance of $1.57M plus equity

## Summary
- CEO Stephen Tang's termination without cause effective March 31, 2022; transition period through that date.
- Tang receives lump sum severance of $1,569,614 (18 months salary plus target bonus).
- 50% of unvested time-based RSUs and PVRUs vest at termination; 2022 LTIP award of $834,909 vests at end.
- Lisa Nibauer becomes President of Diagnostics; salary raised to $460,000 and bonus target to 50%.
- Kathleen G. Weber becomes President of Molecular Solutions; salary raised to $460,000 and bonus target to 50%.

## SEC filing metadata
- accession: 0000950170-22-000095
- form_type: 8-K
- ticker: OSUR
- cik: 0001116463
- company_name: ORASURE TECHNOLOGIES INC
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/0000950170-22-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/osur-20211231.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000095
- JSON: https://secwatch.observer/filing/0000950170-22-000095.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000095.txt

## Key facts
- Executive change
  Stephen S. Tang departed as President and Chief Executive Officer at ORASURE TECHNOLOGIES INC.
  - Action: leaving
  - Role: President and Chief Executive Officer
  source text: Stephen S. Tang, the Company’s President and Chief Executive Officer, will be leaving the Company as of March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/0000950170-22-000095-index.htm
- Executive change
  Lisa Nibauer changed role as President of Diagnostics at ORASURE TECHNOLOGIES INC.
  - Action: promoted
  - Role: President of Diagnostics
  source text: Effective as of December 31, 2021, Lisa Nibauer, the Company’s current Executive Vice President, Business Unit Leader, Diagnostics, will become President of Diagnostics.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1116463/000095017022000095/0000950170-22-000095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.